. 2018 Sep 5;15(1):220–227. doi: 10.1080/21645515.2018.1509172

Table 1.

Characteristics of the 27 studies included in the meta-analysis.

NO	Author	Design	Year	Age	Gender	No	vaccine	dosage	schedule	population characteristics	Geometric mean titer (IU/L)	seroprotective rate anti-HBs ≥ 10 IU/L
1	Chen W. G. et al.	RCT	2001	18–20	NA	138	CHO	10 µg	0.1.6	seronegative students	NA	100.00%
1	Chen W. G. et al.	RCT	2001	18–20	NA	149	CHO	10 µg	0.1.2	seronegative students	NA	97.99%
2	Wang C. X. et al.	RCT	2002	18–55	38/55	93	YDV	5 µg	0.1.2	seronegative adults	18.88	68.82%
2	Wang C. X. et al.	RCT	2002	18–55	35/71	106	YDV	10 µg	0.1.2	seronegative adults	54.47	84.91%
3	Yuan Y. B. et al.	RCT	2003	20–60	NA	48	YDV	5 µg	0.1.6	seronegative teachers	193.37	75.00%
						49	YDV	10 µg	0.1.6		315.58	91.84%
						47	YDV	20 µg	0.1.6		477.81	97.87%
4	Chen Y. Z. et al.	RCT	2005	15–60	NA	92	YDV	5 µg	0.1.2	seronegative adults	34.45	72.83%
						85	YDV	10 µg	0.1.2		41.16	77.65%
						91	YDV	5 µg	0.1.6		48.15	83.52%
						85	YDV	10 µg	0.1.6		67.91	89.41%
						159	CHO	10 µg	0.1.2		42.59	84.28%
						190	CHO	20 µg	0.1.2		77.90	90.53%
						170	CHO	10 µg	0.1.6		76.98	88.24%
						192	CHO	20 µg	0.1.6		123.82	97.40%
5	Li W. Q. et al.	RCT	2008	17–21	29/31	60	YDV	10 µg	0.1.6	seronegative students	NA	98.30%
					42/18	60	CHO	10 µg	0.1.6		NA	95.00%
					25/35	60	CHO	20 µg	0.1.6		NA	96.70%
					37/21	58	Engerix-B	20 µg	0.1.6		NA	96.50%
6	Dong M. H. et al.	RCT	2009	20–55	200/101	301	YDV	5 µg	0.1.6	seronegative adults	NA	94.40%
6	Dong M. H. et al.	RCT	2009	20–55	231/101	332	YDV	10 µg	0.1.6	seronegative adults	NA	94.60%
7	Ji X. L. et al.	RCT	2009	＞20	NA	238	CHO	10 µg	0.1.6	seronegative adults	NA	96.20%
7	Ji X. L. et al.	RCT	2009	＞20	NA	267	YDV	10 µg	0.1.6	seronegative adults	NA	95.90%
8	Zhang W. et al.	RCT	2011	18–45	141/180	321	CHO	10 µg	0.1.6	seronegative adults	NA	88.80%
8	Zhang W. et al.	RCT	2011	18–45	129/192	321	CHO	20 µg	0.1.6	seronegative adults	NA	95.30%
9	Liu C. C. et al.	RCT	2012	18–45	NA	114	CHO	10 µg	0.1.6	seronegative adults	134.57	89.47%
9	Liu C. C. et al.	RCT	2012	18–45	NA	108	CHO	20 µg	0.1.6	seronegative adults	921.11	99.07%
10	Yu S. F. et al.	RCT	2012	16–49	NA	241	YDV	10 µg	0.1.3	seronegative adults	107.97	76.76%
						290	YDV	10 µg	0.1.6		306.90	86.21%
						240	YDV	10 µg	0.1.12		587.49	89.17%
11	Guo Y. H. et al.	RCT	2013	18–74	NA	140	CHO	20 µg	0.1.6	seronegative adults	1230.3	99.40%
11	Guo Y. H. et al.	RCT	2013	18–74	NA	140	Engerix-B	20 µg	0.1.6	seronegative adults	602.6	97.00%
12	Chen S. Y. et al.	RCT	2013	16–49	NA	190	YDV	10 µg	0.1.3	seronegative adults	94.96	88.95%
12	Chen S. Y. et al.	RCT	2013	16–49	NA	191	YDV	10 µg	0.1.6	seronegative adults	145.12	90.05%
13	Liu J. Y. et al.	RCT	2013	18–49	NA	2011	YDV	20 µg	0.1.6	seronegative adults	NA	85.78%
13	Liu J. Y. et al.	RCT	2013	18–49	NA	2290	CHO	20 µg	0.1.6	seronegative adults	NA	90.65%
14	Xu M. Q. et al.	RCT	2013	18–35	NA	60	YDV	10 µg	0.1.6	seronegative adults	NA	75.00%
						60	YDV	20 µg	0.1.6		NA	93.30%
						60	Engerix-B	20 µg	0.1.6		NA	95.00%
15	Xu F. et al.	RCT	2013	16–49	99/267	366	YDV	10 µg	0.1.3	seronegative adults	1863.60	98.36%
					88/174	262	YDV	10 µg	0.1.6		883.85	96.18%
					52/88	140	Engerix-B	20 µg	0.1.3		629.59	97.86%
					72/100	172	Engerix-B	20 µg	0.1.6		993.09	95.35%
16	Huang X. Y. et al.	RCT	2014	17–59	NA	65	YDV	10 µg	0.1.6	seronegative adults	202.99	89.04%
16	Huang X. Y. et al.	RCT	2014	17–59	NA	72	CHO	10 µg	0.1.6	seronegative adults	201.98	91.14%
17	Song J. P. et al.	RCT	2014	≥ 16	NA	591	YDV	20 µg	0.1.6	seronegative adults	575.40	99.15%
17	Song J. P. et al.	RCT	2014	≥ 16	NA	254	YDV	10 µg	0.1.6	seronegative adults	422.30	96.46%
18	Fu Q. P. et al.	RCT	2015	≥ 16	NA	479	YDV	10 µg	0.1.6	seronegative adults	718.86	98.96%
18	Fu Q. P. et al.	RCT	2015	≥ 16	NA	523	YDV	20 µg	0.1.6	seronegative adults	1112.34	98.66%
19	Zhou Y. et al.	RCT	2015	16–49	NA	217	CHO	20 µg	0.1.3	seronegative adults	31.99	63.59%
19	Zhou Y. et al.	RCT	2015	16–49	NA	218	CHO	20 µg	0.1.12	seronegative adults	893.53	95.87%
20	Li J. et al.	RCT	2015	20–46	66/93	159	YDV	10 µg	0.1.3	seronegative adults	91.69	88.05%
20	Li J. et al.	RCT	2015	20–46	30/71	101	YDV	20 µg	0.1.3	seronegative adults	290.23	94.06%
21	Zhang L. et al.	RCT	2015	18–49	59/59	118	YDV	20 µg	0.1.6	seronegative adults	88.14	88.14%
21	Zhang L. et al.	RCT	2015	18–49	65/68	133	CHO	20 µg	0.1.6	seronegative adults	90.23	90.22%
22	Zhou B. Q. et al.	RCT	2015	16–49	NA	151	YDV	10 µg	0.1.3	seronegative adults	807.98	98.01%
						174	YDV	10 µg	0.1.6		930.68	99.43%
						189	YDV	10 µg	0.1.12		720.28	93.65%
23	Guo M. J. et al.	RCT	2015	16–49	NA	254	YDV	10 µg	0.1.3	seronegative adults	128.75	99.61%
						212	YDV	10 µg	0.1.6		381.27	100.00%
						200	Engerix-B	20 µg	0.1.3		249.70	99.50%
						182	Engerix-B	20 µg	0.1.6		498.09	100.00%
24	Cao Y. et al.	RCT	2016	18–21	361/289	650	YDV	20 µg	0.1.3	seronegative students	486.96	89.70%
24	Cao Y. et al.	RCT	2016	18–21	361/289	650	YDV	20 µg	0.1.6	seronegative students	407.91	95.70%
25	Wang H. et al.	RCT	2016	25–55	125/168	293	YDV	20 µg	0.1.6	seronegative adults	1033.38	93.17%
					126/163	289	YDV	20 µg	0.1.6		600.75	97.23%
					126/167	293	CHO	20 µg	0.1.6		1627.05	98.98%
26	Yang L. N. et al.	RCT	2016	16–50	99/144	243	YDV	10 µg	0.1.6	seronegative adults	304.11	100.00%
					50/101	151	YDV	10 µg	0.1.6		906.07	100.00%
					107/143	250	CHO	10 µg	0.1.6		330.33	99.60%
					65/86	151	Engerix-B	10 µg	0.1.6		453.25	100.00%
					51/59	110	CHO	20 µg	0.1.6		142.98	99.10%
					48/83	131	Engerix-B	20 µg	0.1.6		1335.45	96.90%
27	Wen Q. et al.	RCT	2017	18–55	NA	160	YDV	20 µg	0.1.3	seronegative adults	NA	98.13%
27	Wen Q. et al.	RCT	2017	18–55	NA	160	YDV	20 µg	0.1.6	seronegative adults	NA	97.50%

RCT: randomized controlled trial; NA: not available; YDV: yeast-derived recombinant vaccines; CHO: recombinant hepatitis vaccine made by Chinese hamster ovary cells; Engerix-B: a hepatitis B vaccine made by Glaxo Smith Klin.